0000000000936468

AUTHOR

Salvatore Mazzarisi

showing 1 related works from this author

Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients

2019

Background: We investigated whether early dynamic changes of circulating free (cfDNA) levels as well as the neutrophil to lymphocyte ratio (NLR) could predict nivolumab effectiveness in pretreated patients with advanced non-small cell lung cancer (NSCLC). Methods: A total of 45 patients receiving nivolumab 3 mg/kg every 2 weeks were enrolled. Patients underwent a computed tomography scan and responses were evaluated by the response evaluation criteria in solid tumors. Peripheral blood samples were obtained from the patients and the cfDNA level as well as the NLR were assessed. Time to progression (TTP) and overall survival (OS) were determined. Results: Patients with increased cfDNA >20%…

0301 basic medicineOncologymedicine.medical_specialtySettore MED/06 - Oncologia Medicamedicine.medical_treatmentnon-small cell lung cancer (NSCLC)Circulating free DNA (cfDNA)blood-based biomarkers; Circulating free DNA (cfDNA); immunotherapy; neutrophil to lymphocyte ratio (NLR); non-small cell lung cancer (NSCLC)lcsh:RC254-28203 medical and health sciences0302 clinical medicineInternal medicinemedicineNeutrophil to lymphocyte ratioOriginal Researchblood-based biomarkerbusiness.industryBlood based biomarkersblood-based biomarkersImmunotherapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseneutrophil to lymphocyte ratio (NLR)non-small cell lung cancer (NSCLC)030104 developmental biologyOncologyBlood biomarkers030220 oncology & carcinogenesisimmunotherapyNivolumabbusiness
researchProduct